Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab

OBJECTIVES: Disease-modifying therapies (DMTs) can slow disease progression in multiple sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) progression among newly diagnosed people with MS in relation to the first DMT received. DESIGN AND SETTING: A cohort study usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Karampampa, Korinna, Gyllensten, Hanna, Friberg, Emilie, Murley, Chantelle, Kavaliunas, Andrius, Hillert, Jan, Olsson, Tomas, Alexanderson, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193087/
https://www.ncbi.nlm.nih.gov/pubmed/37192793
http://dx.doi.org/10.1136/bmjopen-2022-067516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193087/
https://www.ncbi.nlm.nih.gov/pubmed/37192793
http://dx.doi.org/10.1136/bmjopen-2022-067516

Ejemplares similares